Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

{
  "signal_id": "4f931c32-61ef-af0f-4774-dda3e9ba4106",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-14T05:00:00+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html",
    "title": "Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency",
    "excerpt": "NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial ( NCT05477524 ), which investigated whether the vaccine candidate, PF-07307405, prevented Lyme disease cases in individuals aged five years and older. The vaccine was well tolerated in the trial, with no safety concerns identified.0F 1 “I’m proud of the progress we have made with our Lyme disease vaccine candidate and excited about the opportunity to potentially bring the first vaccine of its kind to Europe. I look forward to collaborating with the EMA as this vaccine candidate advances through the review cycle,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. “Lyme disease remains the most common vector-borne illness in Europe, affecting more than 100,000 people each year. When left untreated, it can lead to serious and potentially long-lasting complications involving the skin, joints...",
    "product": "PF-07307405",
    "summary": "Pfizer and Valneva's Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405, has been validated by the European Medicines Agency (EMA), which will now begin its assessment.",
    "location": "Europe",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/04f398df-96ac-4b7a-8544-2a2ce2495778",
    "confidence": 0.95,
    "product_data": {
      "name": "PF-07307405",
      "full_text": "6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-14T05:00:00Z",
    "location_data": [
      {
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-14",
    "article_sentence": "Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.",
    "related_company_name": "Valneva",
    "related_company_domain": "valneva.com"
  }
}

curl https://signals.autobound.ai/v1/signals/4f931c32-61ef-af0f-4774-dda3e9ba4106 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'